Press Release

Recall of Deltapharm's Anlina Vaginal Tablet

10 Dec 2010

The Department of Health (DH) has today (December 10) instructed licensed drug wholesaler Deltapharm Limited to recall its product Anlina Vaginal Tablet (Registration No. HK-43469) from clients because the drug was found to disintegrate slower than acceptable by DH’s surveillance for disintegration quality.

Initial investigation revealed that the above wholesaler had imported a total of 1 056 boxes (100 tablets each) of the product (Batch No. 0T59001) in July and August 2009 from Thailand. Through Suntol Medical Limited, another licensed drug wholesaler, the product was distributed to pharmacies and registered medical practitioners.

So far, no adverse report has been received.

Anlina Vaginal Tablet, a prescription drug containing nystatin, chloramphenicol and diiodohydroxyquinoline, is used for the treatment of vaginal infection. The tablet can only be sold in pharmacies on doctor's prescription and under the supervision of pharmacist.

Deltapharm Limited has set up a hotline (3113 6103), to operate daily between 9 am and 5 pm, from Monday to Friday to answer public enquiries. DH will closely monitor the recall.

Healthcare professionals are urged to stop supplying the concerned product to clients.

Members of the public who possess the product should stop using it and seek advice from healthcare professionals if in doubt.

Investigation continues.